Abstract
JJ Wildfire, PJ Gergen, CA Sorkness. J Allergy Clin Immunol. 2012;129(3):694–701 To develop and validate a new instrument, the Composite Asthma Severity Index (CASI), which accounts for impairment, risk, and amount of medication to maintain control. Previous instruments do not take into account these measures in defining severity as outlined by the Expert Panel Report—3: For the Diagnosis and Management of Asthma . Data from 546 children and adolescents in the Asthma Control Evaluation (ACE) trial were used initially to determine outcome domains of asthma. External validation of the severity index was achieved by using data from 419 children and adolescents in the Inner City Anti-IgE Therapy for Asthma (ICATA) trial, a double-blind, placebo-controlled multicenter trial of omalizumab versus …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
